Company news

Adocia Sa (EURONEXT:ADOC) news

Every Adocia Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.

View Adocia Sa stock analysis →

Press releases & updates

Number of Shares and Voting Rights of ADOCIA as of August 31st, 2026

September 10, 2026

ADOCIA Announces Changes in its Board of Directors with the Appointment of a New Director and a Board Observer

September 1, 2026

Number of Shares and Voting Rights of ADOCIA as of July 31st, 2026

August 24, 2026

ADOCIA Reports Second Quarter 2026 Financial Results and Provides a Business Update

July 23, 2026

Number of Shares and Voting Rights of ADOCIA as of June 30, 2026

July 7, 2026

ADOCIA Announces the Expiration of Exclusive Right to Negotiate Partnership for M1Pram with SANOFI

July 3, 2026

Number of Shares and Voting Rights of ADOCIA as of May 31st, 2026

June 11, 2026

ADOCIA Announces THDB0206 (BioChaperone® Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions, Confirming th...

June 8, 2026

Adocia Announces a Virtual KOL Event to Review the Phase 3 Results of the Ultra-Rapid Insulin BioChaperone® Lispro on June 16, 2026

June 4, 2026

ADOCIA Reports First Quarter 2026 Financial Results and Provides a Business Update

May 12, 2026

ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 3rd, 2026 in Paris

May 11, 2026

ADOCIA Announces the Release of its Universal Registration Document for the Year 2025

April 29, 2026

ADOCIA Announces Full Year 2025 Financial Results and Provides a Corporate and Financial Update

April 21, 2026

ADOCIA and Vester Finance sign a shareholder loan agreement, enabling ADOCIA to extend its cash runway until beginning Q2 2027

April 21, 2026

ADOCIA Reports Fourth Quarter 2025 Financial Results and Provides a Business Update

February 24, 2026

ADOCIA Announces Half-Year Report on Adocia’s Liquidity Agreement with Kepler Capital Markets

January 22, 2026

ADOCIA Announces its Financial Calendar for 2026

December 18, 2025

ADOCIA Announces the Completion of a €10 Million Fundraising

December 4, 2025

ADOCIA Announces Filing of Patent for New Long-Acting Peptides Platform in Diabetes and Obesity - AdoXLong™ - and Provides an Update on i...

November 12, 2025

ADOCIA Reports Third Quarter 2025 Financial Results and Provides a Business Update

October 15, 2025

ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0...

October 15, 2025

ADOCIA Announces First Half 2025 Financial Results and Provides a Business Update

September 25, 2025

ADOCIA Announces Oral Presentations on AdoShell® and BioChaperone® at EASD, ESB and PODD 2025 Annual Meetings

September 3, 2025

ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0...

July 25, 2025

ADOCIA Reports Second Quarter 2025 Financial Results and Provides a Business Update

July 23, 2025

ADOCIA Presentations at ADA & IPITA Scientific Conferences Highlight Scalability and Good Translation of AdoShell® from Human Islets to S...

June 24, 2025

ADOCIA Confirms its Eligibility for the PEA‑PME Scheme

May 22, 2025

ADOCIA Announces its Annual Shareholders’ Meeting to be Held on June 11th, 2025 in Paris

May 21, 2025

ADOCIA Reports First Quarter 2025 Financial Results and Provides a Business Update

May 14, 2025

ADOCIA to Present New Data on AdoShell® at Upcoming Scientific Conferences – Showcasing Potential Curative Treatment for Type 1 Diabetes

April 28, 2025